-
Cutting-edge bioconjugation technology for ADCs
Time of Update: 2023-01-04
Badescu and al reported a novel site-specific rebridging conjugation strategy in 2014, and they were the first to demonstrate that the new bis-sulfone is able to alkylate two sulfhydryl groups from antibody and antibody fragments that reduce disulfide bonds with minimal effect on antigen binding.
-
Diagnosis and treatment of medulloblastoma in adults
Time of Update: 2023-01-01
Enrico Franceschi of the University of Bologna in Italy discussed histology and molecular typing, imaging diagnosis, surgery, chemoradiotherapy, novel targeted therapies and future research directions for adult medulloblastoma, and the results were published online in Cancers in July 2022.
-
Spatially resolved multiomics interpretation of tumor-host bidirectional dependence in GBM
Time of Update: 2023-01-01
The study elucidates the transcription program profile of the GBM region and maps the microenvironment landscape, including metabolism and tumor-host cell interactions.
-
Grading studies of gliomas according to 11C-acetate PET/CT
Time of Update: 2023-01-01
11C-acetate has a significant advantage over radiation-labeled amino acids in differentiating oligodendroglioma from high-grade glioma, and the mean 11C-acetate TCR value is significantly lower than that of grade 4 IDH1 wild-type glioma in WHO-3 oligodendroglioma.
-
Melanoma pathology experts talked about BRAF gene testing management and treatment decisions
Time of Update: 2022-12-30
↓↓↓ Click "Read Original" to learn more clinical skills*For medical professionals onlyMelanoma is a highly malignant tumor that originates in melanocytes and can occur in different parts of the skin, mucous membranes, eyes and so on.
-
2022 CCO Full of hope and coping with challenges, Professor Xu Quan talked about the concept of early diagnosis and treatment of gastric cancer and the popularization of cancer science
Time of Update: 2022-12-30
From November 17th to 20th, the 2022 Chinese Oncology Congress (CCO) was successfully held in Hangzhou. With the theme of "Cancer Prevention and Treatment, Winning in Integration", this conference foc
-
Up to 73% success rate! NEJM: Immunotherapy targeting bone marrow cancer cells has achieved great success, or a new hope for blood cancer patients!
Time of Update: 2022-12-30
On December 13, 2022, the New England Journal of Medicine (NEJM) reported a new research advance in which researchers used a new treatment that allows the immune system to kill bone marrow cancer cells in a worldwide clinical trial, the results showed It has been successful in as many as 73% of patients, and the drug used in this study is the bispecific antibody Talquetamab.
-
2022 ASH Review| Professor Liang Yang: CBF-AML with different molecular characteristics has different prognosis, and treatment regimens containing TKI may be effectively reversed
Time of Update: 2022-12-30
Research methodsThe investigators analyzed the clinical and molecular characteristics and survival outcomes of 304 patients with CBF-AML aged 18 to 59 years, of which 186 had INV(16)/t (16; 16)AML； In 118 cases, t(8; 21)AML。 These patients received similar treatment in the Cancer & Leukemia Group B/Oncology Clinical Trials Alliance between 1986-2016 and achieved complete remission after receiving standard cytarabine/anthracycline-induction therapy and HiDAC therapy.
-
CUA 2022 Professor Huang Jian: Precise targeting + combination therapy, the future battle of bladder cancer should be fought like this
Time of Update: 2022-12-30
Professor Huang Jian mentioned that immunotherapy + chemotherapy has become a popular choice for the treatment of bladder cancer, and has good results in advanced bladder cancer treatment, maintenance therapy, and neoadjuvant therapy, and many studies of immune + targeted therapy are underway, including PD-1/PD-L1 inhibitor + ADC, PD-1/PD-L1 inhibitor + RTK inhibitor, PD-1/PD-L1 inhibitor + FGFR inhibitor and so on.
-
2022 ASH raises the possibility of cure, and vipotuzumab escorts the long-term survival of treatment-naïve DLBCL
Time of Update: 2022-12-30
Poke "Read Original" to see morePrevious data from the POLARIX study showed that Pola-R-CHP broke through the efficacy of R-CHOP for the first time, significantly increasing the 2-year PFS rate and 2-year EFS rate, promoting patients to achieve more durable remission and less need for follow-up anti-lymphoma treatment.
-
Multiple myeloma therapeutic target: CRL4 E3 ligase
Time of Update: 2022-12-30
Source: Yaodu Written by: Sunset Graffiti Editor: Maruzi multiple myeloma (MM) is the second most common hematologic malignancy and is prone to recurrence in clinical symptoms. The introduction of imm
-
A picture to read: dabrafenib + trametinib evil black event
Time of Update: 2022-12-30
*For medical professionals only*This article is only used to provide scientific information to medical professionals and does not represent the views of this platform *The "medical community" strives
-
The nutrition care program for cancer patients in China was launched, opening the education of millions of cancer patients
Time of Update: 2022-12-30
On November 26th, the Chinese Cancer Patients Nutrition Management Expert Advisory Association and the Chinese Society of Clinical Oncology (CSCO) Cancer Nutrition Therapy Expert Committee and the la
-
2022 SABCS Big Coffee Talk| Professor Lili Zhang: ADC king, continuous breakthrough, consolidate the standard status of second-line treatment of HER2-positive advanced breast cancer
Time of Update: 2022-12-30
Lili Zhang:The DESTINY-Breast03 study is a randomized, open-label, multicenter phase III study designed to compare the efficacy of T-DXd with T-DM1 in patients with HER2-positive advanced second-line breast cancer who have previously received trastuzumab and taxan therapy 。 The results of this study were first reported at the 2021 ESMO Conference, and the HR of the primary endpoint PFS was only 0.
-
A case sharing of domestic trastuzumab combined with pertuzumab neoadjuvant therapy for HER2-positive/HR-positive breast cancer
Time of Update: 2022-12-30
According to the 2019 Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of breast cancer, patients with HER2-positive breast cancer with tumor volume of > 2 cm or lymph node metastasis at the time of initial diagnosis are recommended neoadjuvant therapy, and the preferred regimen is a dual-target regimen of trastuzumab + pertuzumab combined with chemotherapy[1].
-
How are domestic and foreign guidelines recommended for adjuvant treatment of EGFR mutation NSCLC?
Time of Update: 2022-12-30
▌CSCO NSCLC diagnosis and treatment guidelines According to the Chinese Society of Clinical Oncology (CSCO) NSCLC diagnosis and treatment guidelines (2022 edition), the treatment of NSCLC still adopts comprehensive treatment based on pathological type, stage (according to the 8th edition of lung cancer staging criteria) and molecular classification [2]。 Regarding the adjuvant therapy of EGFR mutation-positive NSCLC, guidelines state that for patients with stage IIA, IIB, IIIA, or III.
-
Ang/TAT-sEVs are loaded with specific drugs for the treatment of gliomas
Time of Update: 2022-12-30
Research methods The researchers constructed a dual-peptide-modified functional small extracellular vesicle Ang/TAT-sEVs drug loading system, and verified the targeting, BBB penetration, glioma tissue penetration, anti-tumor activity and related mechanisms of Ang/TAT-sEVs-DOX through in vitro and in vivo cell uptake experiments, BBB models and animal models.
-
First enrollment! The novel GnRH antagonist, Linzagolix, will break the current situation of patients with uterine fibroids who lack drugs that can be taken orally for a long time and have flexible dosage regimens Press Release
Time of Update: 2022-12-30
Professor Xu Congjian, principal investigator of Linzagolix phase III clinical trial of uterine fibroids in China and president of Fudan University Obstetrics and Gynecology Hospital, pointed out:Symptomatic uterine fibroids seriously affect the reproductive health of women of childbearing age, reduce work efficiency and quality of life, and drug treatment should become an important option for their clinical treatment.
-
2022 CCO Professor Shi Jianguo: Early cancer screening helps "Healthy China", the cause is not finished, and the task is heavy and long
Time of Update: 2022-12-30
Professor Shi JianguoProfessor, doctoral supervisor and chief physician of the Department of Pathology/Oncology of the Fourth Military Medical UniversityChairman of Cancer Rehabilitation Association of Chinese Anti-Cancer AssociationChairman of the Children's Brain Health Professional Committee of the China Eugenics and Fertility AssociationMedical Pulse: Malignant tumors have become one of the main public problems threatening the health of our population, why should we do early screening for cancer?
-
Express significantly improves progression-free survival of advanced gastric cancer! Potential "first-in-class" therapies show impressive Phase 3 clinical data
Time of Update: 2022-12-30
2), in combination with chemotherapy, has met its primary endpoint in a Phase 3 clinical trial for the first-line treatment of patients with locally advanced unresectable or metastatic gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma, significantly prolonging progression-free survival (PFS).
